CARDINAL HEALTH INC
Close on Oct 19, 2026
- Market cap
- $59.12B
- P/E (TTM)
- 34.9
- Dividend yield
- 0.81%
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | $63.70B | $1.70 | $2.91 |
| Q3 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $60.90B | $1.69 | $3.17 |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 5, 2026 | Before market open | $65.60B | $1.97 | $2.63 |
| Q1 FY2026 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $64.00B | $1.88 | $2.55 |
| Q4 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $60.20B | $1.00 | $2.08 |
| Q3 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $54.90B | $2.10 | $2.35 |
| Q2 FY2025 Ended Dec 31, 2024 | Jan 30, 2025 | Before market open | $55.30B | $1.65 | $1.93 |
| Q1 FY2025 Ended Sep 30, 2024 | Nov 1, 2024 | Before market open | $52.30B | $1.70 | $1.88 |
| Q4 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | $59.90B | $0.96 | $1.84 |
| Q3 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | $54.90B | $1.05 | $2.08 |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 1, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 11, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital Expenditures | fiscal year 2027 | $700.00M | New |
| non-GAAP EPS growthnon-GAAP | fiscal year 2027 | 13% to 15% growth | New |
| Non-GAAP earnings per sharenon-GAAP | fiscal year 2027 | $12.40 to $12.60 | New |
| Non-GAAP adjusted free cash flownon-GAAP | fiscal year 2027 | $3.50B to $4.00B | New |
| Segment profit | fiscal year 2027 | 8% to 11% growth | New |
| Non-GAAP effective tax ratenon-GAAP | fiscal year 2027 | 19% to 20% | New |
| Diluted weighted average shares outstanding | fiscal year 2027 | 233 | New |
| Interest and other | fiscal year 2027 | $240.00M to $290.00M | New |
| Share repurchases | fiscal year 2027 | $1.00B | Raised |
| Revenue | fiscal year 2027 | 3% to 5% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Cardinal Health filed with the SEC
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health announces the addition of Solaris Health, the country’s leading urology MSO, to The Specialty Alliance
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Cardinal Health Details Momentum and Updated Long-Term Value Creation Plans at Investor Day
Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Robert Musslewhite and Sudhakar Ramakrishna to join
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health announces two strategic additions to its portfolio
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports First Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Fourth Quarter and Fiscal Year 2024 Results and Raises Fiscal Year 2025 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Third Quarter Fiscal Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health, Inc. and Subsidiaries
Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reaffirms Fiscal 2024 non-GAAP EPS Guidance and Long-term Targets Amidst Nonrenewal of OptumRx Customer Contracts
Regulation FD disclosure · EX-99.1 to Form 8-K
Bob Azelby to join Cardinal Health Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Announces Progress on Business and Portfolio Review and Fiscal 2024 Outlook Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports First Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2023 at High End of Investor Day Guidance
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Investor Day to Highlight Long-Term Value Creation
Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Third Quarter Fiscal Year 2023 Results
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Second Quarter Fiscal Year 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Names Aaron Alt Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports First Quarter Fiscal 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Announces Pharmaceutical Segment Organizational Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Announces Governance Enhancements and Shareholder Value Creation Initiatives
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardinal Health Announces Leadership Changes
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
FOR THE SOUTHERN DISTRICT OF OHIO
Other events · EX-99.1 to Form 8-K
Cardinal Health Reports Third Quarter Fiscal 2022 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
List of States and territories that have agreed to opiods-related Settlement:
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Distributors Approve Opioid Settlement Agreement
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Cardinal Health Reports Second Quarter Fiscal 2022 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K